PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9806126
1PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/40, C07D 487/22 — A1

(11) International Publication Number: WO 97/4729

(43) International Publication Date: 18 December 1997 (18.12.97

(21) International Application Number: PCT/US97/09661

(22) International Filing Date: 12 June 1997 (12.06.97)

(30) Priority Data:
08/662,623 13 June 1996 (13.06.96) US

(60) Parent Application or Grant
(63) Related by Continuation
US 08/662,623 (CON)
Filed on 13 June 1996 (13.06.96)

(71) Applicant (*for all designated States except US*): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): JIROUSEK, Michael, R. [US/US]; 10342 Fawn Ridge Lane, Indianapolis, IN 46326 (US). HEATH, William, Francis, Jr. [US/US]; 11214 Tufton Street, Fishers, IN 46038 (US). WAYS, Douglas, Kirk [US/US]; 4565 North Park Avenue, Indianapolis, IN 46205 (US). STRAMM, Lawrence, E. [US/US]; 9143 Hadway Drive, Indianapolis, IN 46256 (US).

(74) Agents: SKERPON, Joseph, M. et al.; Banner & Witcoff, Ltd Suite 1100, 1001 G Street, N.W., Washington, DC 2000 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BF BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THERAPEUTIC TREATMENT FOR CARDIOVASCULAR DISEASES

(57) Abstract

A method for treating endothelial cell dysfunction, such as associated with cardiovascular disease are disclosed, particularly usin the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((27''-ethoxy)-3'''(O)-4'''-(N,N-dimethylamino)-butane)-bis-(3,3'indolyl)]-1(H) pyrrole-2,5-dione hydrochloride salt.